Organizado por Unirisco y Bio&Tech Smart Capital de Noso Capital, el evento pretende impulsar la inversión en transferencia del conocimiento y proyectos disruptivos y poner en valor su relevancia par...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of ...
Thanks to the continued support of Inveready and Sodena, Palobiofarma has become the start-up with the broadest clinical pipeline in Spain, financed basically through licensing agreements such as the ...
Venture capital remains the main source of investment for startups and scaleups, with €114 million (52%). This figure is down from the previous year, mainly due to the cautiousness of financial envi...
BeAble Capital, gestora de fondos de capital privado especializada en Science Equity: inversión en tecnologías Deep Science en fases pre-seed, seed y early stage, y BBVA Research, todo un referente ...
Plan Capital Privado Global FCR will invest around 30% in infrastructure funds, with exposure to mature assets providing essential services to local communities. The remaining 70% will be spread acros...
Un centenar de inversores en ciencia y tecnología nacionales analizaron estas oportunidades en la primera sesión de Invertir en Ciencia sí es rentable, que se celebra en la Facultad de Medicina de ...
La empresa gallega Oncostellae, el programa Ignicia promovido por la Xunta de Galicia y el ecosistema emprendedor Marina de Empresas-Lanzadera, recibieron hoy los premios Invertir en ciencia sí es re...
ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1...
Palobiofarma S.L., backed by Inveready, is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Wi...
Invivo Ventures III is strategically designed to propel the emergent field of synthetic biology, a domain where Invivo has already established a formidable presence through investments in pioneering c...
The Catalan biopharmaceutical company Ability Pharmaceuticals, SA (AbilityPharma), focused on the development of innovative oral autophagy-inducing anticancer compounds, announces a €7M investment f...